Walleye Trading’s Iovance Biotherapeutics IOVA Stock Holding History

Walleye Trading’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,300	Closed	-$22.7K	–	4404
2025 Q4	$22.7K	Buy	+8,300	New	+$19.2K	﹤0.01%	4100
2025 Q1	–	Sell	-35,800	Closed	-$265K	–	4357
2024 Q4	$265K	Buy	+35,800	New	+$332K	﹤0.01%	3072
2024 Q2	–	Sell	-25,500	Closed	-$378K	–	4589
2024 Q1	$378K	Buy	+25,500	New	+$297K	﹤0.01%	2998
2023 Q3	–	Sell	-4,200	Closed	-$29.6K	–	5155
2023 Q2	$29.6K	Buy	+4,200	New	+$30.1K	﹤0.01%	4053
2022 Q1	–	Sell	-18,800	Closed	-$359K	–	5577
2021 Q4	$359K	Buy	18,800 +15,900	+548%	+$350K	﹤0.01%	3289
2021 Q3	$72K	Sell	2,900 -47,800	-94%	-$1.13M	﹤0.01%	4508
2021 Q2	$1.32M	Buy	50,700 +41,600	+457%	+$1.08M	0.01%	1868
2021 Q1	$288K	Buy	+9,100	New	+$377K	﹤0.01%	3263
2020 Q2	–	Sell	-20,000	Closed	-$599K	–	4408
2020 Q1	$599K	Buy	+20,000	New	+$530K	﹤0.01%	1724

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Walleye Trading's IOVA Position: Q1 2026 in Review

Walleye Trading increased its Iovance Biotherapeutics (IOVA) stake by 16% in Q1 2026, buying an estimated $5.95K and bringing the position to 13,812 shares worth $48.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3692.

Walleye Trading first reported a position in IOVA in Q1 2020 and has held it in 11 quarters since. The position peaked at $431K in Q3 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Walleye Trading held 13,812 shares of Iovance Biotherapeutics worth $48.5K as of Q1 2026.
Walleye Trading bought 1,860 Iovance Biotherapeutics shares in Q1 2026, an estimated $5.95K.
Iovance Biotherapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #3692 holding.
Walleye Trading first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 11 quarters since.
Walleye Trading's Iovance Biotherapeutics position peaked at $431K in Q3 2021.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.